NZ719532B2 - Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid - Google Patents
Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid Download PDFInfo
- Publication number
- NZ719532B2 NZ719532B2 NZ719532A NZ71953214A NZ719532B2 NZ 719532 B2 NZ719532 B2 NZ 719532B2 NZ 719532 A NZ719532 A NZ 719532A NZ 71953214 A NZ71953214 A NZ 71953214A NZ 719532 B2 NZ719532 B2 NZ 719532B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- salt
- dihydro
- jennyp
- compound
- dioxo
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 71
- JDARDSVOVYVQST-MRXNPFEDSA-N 1-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)-4-(trifluoromethyl)-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxylic acid Chemical class C1CC(C(=CC=C2)C(F)(F)F)=C2[C@@H]1N(C1=O)C(=O)C(C(O)=O)=CN1C1=CC=C2N(C)C(=O)OC2=C1 JDARDSVOVYVQST-MRXNPFEDSA-N 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 19
- -1 amino acid salts Chemical class 0.000 claims abstract description 16
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 13
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 62
- 208000035475 disorder Diseases 0.000 claims description 37
- 239000002253 acid Substances 0.000 claims description 23
- 238000011321 prophylaxis Methods 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 230000003176 fibrotic effect Effects 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 5
- 230000000172 allergic effect Effects 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 239000012442 inert solvent Substances 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- YPUZOECTETYPRF-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine-2-carboxylic acid Chemical compound OC(=O)C1NCC=CN1 YPUZOECTETYPRF-UHFFFAOYSA-N 0.000 claims 1
- 125000001176 L-lysyl group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 208000017169 kidney disease Diseases 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 230000001154 acute effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 150000008545 L-lysines Chemical class 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 206010019280 Heart failures Diseases 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 201000006370 kidney failure Diseases 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 208000001647 Renal Insufficiency Diseases 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 206010016654 Fibrosis Diseases 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000001434 glomerular Effects 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- 206010025415 Macular oedema Diseases 0.000 description 3
- 208000009525 Myocarditis Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000033626 Renal failure acute Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 201000010230 macular retinal edema Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 201000002327 urinary tract obstruction Diseases 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- RLRMXTVZEDMFHB-VIFPVBQESA-N (1S)-1-(trifluoromethyl)-2,3-dihydroinden-1-ol Chemical compound C1=CC=C2[C@](O)(C(F)(F)F)CCC2=C1 RLRMXTVZEDMFHB-VIFPVBQESA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023439 Kidney transplant rejection Diseases 0.000 description 2
- 101150038444 Ment gene Proteins 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 206010063897 Renal ischaemia Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003601 chymase inhibitor Substances 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000000159 corneal neovascularization Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 201000005991 hyperphosphatemia Diseases 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 201000008284 inappropriate ADH syndrome Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 229960003390 magnesium sulfate Drugs 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- RPGWZZNNEUHDAQ-UHFFFAOYSA-N phenylphosphine Chemical compound PC1=CC=CC=C1 RPGWZZNNEUHDAQ-UHFFFAOYSA-N 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 208000035939 Alveolitis allergic Diseases 0.000 description 1
- 206010068172 Anal pruritus Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002921 Aortitis Diseases 0.000 description 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 108700004676 Bence Jones Proteins 0.000 description 1
- 208000008720 Bone Marrow Neoplasms Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008528 Chillblains Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229940119334 Chymase inhibitor Drugs 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 208000026292 Cystic Kidney disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 1
- 208000027445 Farmer Lung Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000031354 Hyphema Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010029888 Obliterative bronchiolitis Diseases 0.000 description 1
- 208000036576 Obstructive uropathy Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010034545 Periorbital oedema Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 102100038124 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000009544 Pruritus Ani Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 206010037520 Pupillary block Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010038380 Renal artery thrombosis Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010038423 Renal cyst Diseases 0.000 description 1
- 206010038548 Renal vein thrombosis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038886 Retinal oedema Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 1
- 206010044640 Tricuspid valve incompetence Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000035222 X-linked skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 201000003848 bronchiolitis obliterans Diseases 0.000 description 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 208000007413 cholesterol embolism Diseases 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 208000022195 farmer lung disease Diseases 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- DQKGOGJIOHUEGK-UHFFFAOYSA-M hydron;2-hydroxyethyl(trimethyl)azanium;carbonate Chemical compound OC([O-])=O.C[N+](C)(C)CCO DQKGOGJIOHUEGK-UHFFFAOYSA-M 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003114 inden-1-yl group Chemical group [H]C1=C([H])C([H])(*)C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000005907 mitral valve insufficiency Diseases 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000002580 nephropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000003102 pulmonary valve Anatomy 0.000 description 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 208000025869 skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
The invention relates to novel salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)- 4-(trifluormethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid of the formula (I), in particular amino acid salts such as lysine salt and alkali metal salts such as sodium salt and potassium salt, to a method for producing same, to medication containing same, and to the use thereof in treating diseases. as sodium salt and potassium salt, to a method for producing same, to medication containing same, and to the use thereof in treating diseases.
Description
SALTS 0F 1- 3-METHYLOXO-2 -DIHYDRO-l 3-BENZOXAZOL—6-YL -2 4-DIOXO-3— 1TRIFLUORMETHYL{-ZQ-DIHYDRO-lH-INDEN-l-YL|-l,2,§,4-TETRAHYDROPYRIMIDIN-S- CARBOXYLIC ACID The invention relates to novel salts of 1-(3-methyloxo-2,3-dihydro-1,3-benzoxazolyl)-2,4-dioxo[(1R)- 4-(trifluoromethyl)-2,3-dihydro-1H-inden-l-yl]~l,2,3,4-tetrahydropyrimidine-S-carboxylic acid of the a (I), in particular to amino acid salts such as the lysine salt and to alkali metal salts such as the sodium salt and the potassium salt, to ses for their preparation, to medicaments comprising them and their use for control- ling diseases. l-(3-Methyloxo-2,3—dihydro-1,3-benzoxazolyl)-2,4~dioxo[(1R)(t1ifluoromethyl)—2,3-dihydro-1H- inden-l-y1]-1,2,3,4—tetrahydropyn'midinecarboxylic acid, its preparation and its use as chymase inhibitor is described in the patent application (see Example 189) and ponds to the compound of the formula (I): Hereinbelow, the compound of the formula (I) is referred to as free acid.
It has now been found that, for some applications, the free acid has insufficient solubility and is therefore not unconditionally suitable for use in formulations.
Surprisingly, we have now found novel salts. These salts have ly different and in each case characteristic X-ray diffiractograms (Table 1, Figures 1, 2 and 3).
The present invention provides the compound of the formula (I) in the form of its amino acid salts and alkali metal salts.
The present ion provides the compound of the a (I) in the form of its lysine salt, in particular in the form of its L-lysine salt, or in the form of its sodium salt or potassium salt.
The present invention provides the compound of the formula (I) in the form of its L-lysine salt which, in the X- ray ctograrn, has essentially the following preferred peak maximum of the 2 theta angle at 16.9.
[Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp The t invention preferably provides the compound of the a (I) in the form of its L-lysine salt which, in the X-ray diffractogram, has essentially the following preferred peak maxima of the 2 theta angle at 16.9, 22.3 and 20.0.
The present invention furthermore preferably provides the compound of the formula (I) in the form of its L- lysine salt which, in the X-ray diffractogram, has essentially the following preferred peak maxima of the 2 theta angle at 16.9, 22.3, 20.0, 16.7, 19.2, 10.9 and 12.2.
The present invention rmore preferably provides the compound of the formula (I) in the form of its L- lysine salt which, in the X-ray diffractogram, has essentially the following preferred peak maxima of the 2 theta angle at 16.9, 22.3, 20.0, 16.7, 19.2, 9.9 and 21.6. , 10.9, 12.2, Moreover, the present invention provides the compound of the formula (I) in the form of its sodium salt which, in the X—ray diffractogram, has essentially the following preferred peak maximum of the 2 theta angle at 17.6.
The present invention preferably es the compound of the formula (I) in the form of its sodium salt which, in the X-ray diffractogram, has essentially the following preferred peak maxima of the 2 theta angle at 17.6, 17.9 and 19.1.
The present invention furthermore preferably provides the compound of the formula (I) in the form of its sodi~ um salt which, in the X-ray diffractogram, has essentially the following preferred peak maxima of the 2 theta angle at 17.6, 17.9, 19.1, 18.1, 12.8, 5.9 and 18.9.
The present invention furthermore preferably provides the compound of the formula (I) in the form of its sodi- um salt which, in the X-ray diffractogram, has ially the following preferred peak maxima of the 2 theta angle at 17.6, 17.9, 19.1, 18.1, 12.8, 5.9, 29.0 and 19.6. , 18.9, Moreover, the present invention es the compound of the formula (I) in the form of its potassium salt which, in the X-ray diffractogram, has ially the following preferred peak maximum of the 2 theta angle at 23.7.
The present ion preferably provides the nd of the a (I) in the form of its potassium salt which, in the X-ray diffractograin, has essentially the following red peak maxima of the 2 theta angle at 237,153 and 20.5.
The present invention furthermore preferably es the compound of the a (I) in the form of its potas— sium salt which, in the X-ray diffractogram, has essentially the following preferred peak maxima of the 2 theta angle at 23.7, 15.3,, 20.5, 10.4, , 30.0, 21.7 and 6.00.
The present invention furthermore preferably provides the compound of the formula (I) in the form oifinas- sium salt which, in the X-ray diffractogram, has essentially the following preferred peak maxima of heta angle at 23.7, 15.3, , 20.5, 10.4, , 30.0, 21.7, 6.0, 19.8 and 18.0.
[Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp ation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp General aspects in connection with the present invention are pharmacological properties, processability, prepa— ration process, ffect profile, stability and pharmacological activity in particular of the salt with L-lysine of the compound of the formula (I).
Surprisingly, the L-lysine salt and the sodium and ium salt of the compound of the formula (I) are crystal- line and, even after processing via suspensions, e-stable. Accordingly, they are particularly suitable for use in pharmaceutical formulations such as suspensionen or creams, but also in other preparations prepared via the suspended active nd, such as, for example, in the case ofwet granulation or wet grinding.
In pharmaceutical ations, the salts according to the invention of the compound of the formula (I), in par- ticular the L—lysine salt and the sodium and potassium salt, are employed in high purity. For reasons of stability, a pharmaceutical formulation comprises mainly a salt of the nd of the formula (I), in ular either the L-lysine salt or the sodium or potassium salt, and no r tions of any other form of the compound of the formula (I). Preferably, the medicament comprises more than 90 t by weight, ularly prefera< bly more than 95 percent by , of the compound of the formula (I) in the form of the corresponding salt, based on the total amount of the compound of the formula (I) present.
The salts of the invention have valuable pharmacological properties and can be used for treatment and/or prophylaxis of diseases in humans and animals. The salts of the invention are chymase inhibitors and are there- fore suitable for treatment and/or prophylaxis of cardiovascular, inflammatory, allergic and/or fibrotic disorders.
In the context of the present invention, disorders of the cardiovascular system or vascular disorders are understood to mean, for example, the following disorders: acute and chronic heart failure, arterial hypertension, coronary heart disease, stable and unstable angina pectoris, myocardial ischemia, myocardial infarction, shock, sclerosis, cardiac hypertrophy, cardiac fibrosis, atrial and ventricular arrhythmias, transitory and ischaem- ic attacks, stroke, pre-eclampsia, inflammatory cardiovascular disorders, peripheral and cardiac vascular disor- ders, peripheral perfusion disorders, arterial pulmonary hypertension, spasms of the coronary arteries and pe- ripheral arteries, thromboses, thromboembolic disorders, edema deve10pment, for example pulmonary edema, cerebral edema, renal edema or heart failure-related edema, and restenoses such as after thrombolysis treat- ments, percutaneous transluminal angioplasty (PTA), transluminal coronary angioplasty (PTCA), heart trans- plants and bypass operations, and micro- and ascular damage (vasculitis), reperfusion damage, al and venous thromboses, microalbuminuria, myocardial insufficiency, endothelial dysfunction, peripheral and cardiac vascular disorders, peripheral perfusion disorders, heart failure»related edema, elevated levels of fibrin- ogen and of low—density LDL and elevated concentrations of plasminogen tor/inhibitor I (PAI-l).
In the context of the present invention, the term "heart failure" also includes more specific or related types of disease, such as acutely decompensated heart e, right heart failure, left heart failure, global failure, is- chaemic cardiomyopathy, dilated cardiomyopathy, congenital heart s, heart valve defects, heart e associated with heart valve defects, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosflortic valve insufficiency, tiicuspid stenosis, tricuspid insufficiency, pulmonary valve stenosis, pulmonary valve in- sufficiency, combined heart valve defects, myocardial mation (rnyocarditis), c myocarditis, acute [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, cardiac storage disorders, and diastolic and ic heart failure.
The salts according to the ion are further suitable for the laxis and/or treatment of polycystic kid« ney e (PCKD) and of the syndrome of inapprOpriate ADH secretion (SIADH). The salts of the invention are also suitable for treatment and/or prOphylaxis of kidney disorders, in particular of acute and chronic renal insufficiency and acute and chronic renal failure.
In the context of the t invention, the term "acute renal insufficiency" encompasses acute manifestations of kidney disease, of kidney failure and/or renal iciency with and without the need for dialysis, and also ying or d renal disorders such as renal hypoperfusion, intradialytic hypotension, volume deficiency (eg. dehydration, blood loss), shock, acute glomerulonephn'tis, hemolytic-uremic syndrome (HUS), vascular catastrophe (arterial or venous thrombosis or embolism), cholesterol embolism, acute Bence-Jones kidney in the event of plasmacytoma, acute supravesicular or subvesicular efflux obstructions, immunological renal ers such as kidney transplant rejection, immune x-induced renal disorders, tubular dilatation, hyperphos- phatemia and/or acute renal disorders characterized by the need for dialysis, including in the case of partial re- sections of the kidney, dehydration through forced is, uncontrolled blood pressure rise with malignant hy~ pertension, urinary tract obstruction and infection and amyloidosis, and systemic disorders with glomerular fac- tors, such as rheumatological-immunological systemic disorders, for example lupus erythematodes, renal artery thrombosis, renal vein thrombosis, analgesic nephropathy and renal tubular acidosis, and X-ray contrast agent- and ment-induced acute titial renal disorders.
In the context of the present invention, the term "chronic renal insufficiency" encompasses chronic sta- tions of kidney disease, of kidney failure and/or renal insufficiency with and without the need for dialysis, and also underlying or d renal disorders such as renal hypoperfusion, intradialytic hypotension, obstructive uropathy, glomeruIOpathy, glomerular and tubular nuria, renal edema, hematuria, primary, secondary and chronic glomerulonephritis, membranous and membranoproliferative glomerulonephritis, Alport syndrome, glomerulosclerosis, tubulointerstitial disorders, nephropathic disorders such as primary and congenital kidney disease, renal inflammation, immunological renal disorders such as kidney transplant rejection, immune com- plex~induced renal disorders, diabetic and abetic pathy, ephritis, renal cysts, nephrosclero- sis, hypertensive nephrosclerosis and nephrotic syndrome, which can be characterized diagnostically, for exam- ple, by abnormally reduced creatinine and/or water excretion, abnormally elevated blood concentrations of urea, nitrogen, potassium and/or creatinine, altered activity of renal enzymes, for example glutamyl synthetase, al- tered urine osmolarity or urine volume, elevated microalbuminuiia, macroalbuminuria, glomerular and arterio- lar lesions, tubular dilatation, hyperphosphatemia and/or the need for is, and in the event of renal cell car- cinoma, after partial resections of the kidney, dehydration through forced diuresis, uncontrolled blood pressure rise with malignant hypertension, urinary tract obstruction and ion and amyloidosis, and systemic disor- ders with glomerular factors, such as rheumatological-immunological systemic disorders, for example s er- ythematodes, and also renal artery stenosis, renal artery osis, renal vein osis, analgesic ntgopathy and renal tubular is. In addition, X-ray contrast agent— and medicament-induced chronic interstitial [Annotation] jennyp None set by jennyp [Annotation] jennyp ionNone set by jennyp [Annotation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp renal disorders, metabolic syndrome and dyslipidernia. The present ion also encompasses the use of the compounds of the invention for the ent and. or prophylaxis of sequelae of renal insufficiency, for example pulmonary edema, heart failure, uremia, anemia, electrolyte disorders (for example hyperkalernia, hyponatremia ) and disorders in bone and carbohydrate metabolism.
In addition, the salts according to the invention are also suitable for treatment and/or prophylaxis of pulmonary al hypertension (PAH) and other forms of ary hypertension (PH), of chronic obstructive ary disease (COPD), of acute respiratory distress syndrome (ARDS), of acute lung injury (ALI), of alpha antitrypsin deficiency (AATD), of pulmonary fibrosis, of pulmonary emphysema (for example pulmonary em- physema caused by cigarette , of cystic s (CF), of acute coronary me (ACS), heart muscle inflammation (myocarditis) and other autoimmune cardiac disorders (pericarditis, endocarditis, valvolitis, aorti— tis, cardiomyopathy), genic shock, aneurysms, sepsis (SIRS), multiple organ failure (MODS, MOP), in- flammation disorders of the kidney, chronic intestinal disorders (IBD, Crohn's Disease, UC), pancreatitis, peri- tonitis, rheumatoid disorders, inflammatory skin disorders and atory eye disorders.
The salts according to the invention can rmore be used for ent and/or prophylaxis of asthmatic dis- orders of varying severity with intermittent or persistent teristics (refractive asthma, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, medicament- or dust-induced asthma), of various forms of bronchitis (chronic bronchitis, infectious bronchitis, eosinophilic bronchitis), of Bronchiolitis obliterans, bron- chiectasis, pneumonia, idiopathic interstitial pneumonia, farmer's lung and related disorders, of coughs and colds (chronic inflammatory cough, iatrogenic cough), ation of the nasal mucosa (including medica- ment~related is, vasomotoric rhinitis and seasonal allergic rhinitis, for example hay fever) and ofpolyps.
The salts ing to the invention are also suitable for treatment and/or prophylaxis of fibrotic disorders of the internal organs, for example the lung, the heart, the kidney, the bone marrow and in particular the liver, and also dermatological fibroses and fibrotic eye disorders. In the context of the present invention, the term "fibrotic dis- orders" encompasses particularly the following terms: hepatic fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, cardiomyopathy, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage ing from es, bone marrow fibrosis and similar fibrotic disorders, sclerodemra, a, ke- loids, hypertrophic scarring (also ing surgical procedures), rraevi, diabetic retinopathy and proliferative vitroretinopathy.
The salts according to the invention are also suitable for controlling postoperative scarring, for example as a re- sult of glaucoma operations.
Furthermore, the salts according to the invention can also be used cosmetically for ageing and keratinized skin.
In addition, the salts of the invention can also be used for treatment and/or prophylaxis of dyslipidemias (hyper- terolemia, hypertriglyceridemia, elevated trations of the andial plasma triglyceridespoal- phalipoproteinemia, combined hyperlipidenrias), nephropathy and neuropathy), cancers (skin cancer, rain tu- mors, breast cancer, bone marrow tumors, leukemias, liposarcomas, carcinoma of the gastrointestinal tract, of [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp ed set by jennyp the liver, as, lung, kidney, urinary tract, prostate and genital tract, and also malignant tumors in the lyin- liferative system, for example Hodgkin‘s and non—Hodgkin's lymphoma), of ers of the gastrointes- tinal tract and of the abdomen (glossitis, gingivitis, periodontitis, esophagitis, philic gastroenteritis, mas- tocytosis, Crohn‘s e, colitis, proctitis, pruritus ani, diarrhea, celiac disease, hepatitis, chronic hepatitis, hepatic fibrosis, cirrhosis of the liver, pancreatitis and cholecystitis), skin disorders (allergic skin disorders, psoria- sis, acne, eczema, neurodennitis, various forms of dermatitis, and also keratitis, bullosis, vasculitis, cellulitis, panniculitis, lupus erythematodes, erythema, lymphoma, skin cancer, Sweet's syndrome, Weber-Christian syndrome , ng, warts, chillblains), of disorders of the skeletal bone and of the joints, and also of the skeletal muscle (various forms of arthritis, various forms of arthropathies, sclerodenna and of r disorders with an inflammatory or immunological component, for example paraneoplastic me, in the event of rejection re- actions afier organ transplants and for wound healing and angiogenesis, especially in the case of chronic wounds.
The salts according to the invention are additionally suitable for ent and/or prophylaxis of ophthalmolog- ic disorders, for example ma, normotensive glaucoma, high intraocular pressure and combinations there- of, of age-related r degeneration (AMD), of dry or udative AMD, moist or exudative or neovascu- lar AMD, choroidal neovascularization (CNV), detached retina, ic retinopathy, atrophic changes to the retinal pigment epithelium (RPE), hypertrophic s to the retinal pigment epithelium (RPE), ic macular edema, retinal vein occlusion, choroidal retinal vein occlusion, macular edema, macular edema due to retina] vein occlusion, angiogenesis at the front of the eye, for example corneal angiogenesis, for example fol- lowing keratitis, cornea transplant or keratoplasty, corneal angiogenesis due to hypoxia (extensive wearing of contact ), pterygium ctiva, subretinal edema and intraretinal edema.
In addition, the salts according to the invention are suitable for the ent and/or prophylaxis of elevated and high intraocular re resulting from traumatic hyphema, periorbital edema, postoperative viscoelastic reten- tion, intraocular inflammation, use of corticosteroids, pupillary block or idiopathic causes, and of elevated in- traocular pressure following trabeculectomy and due to pure-operative conditions.
The present invention further provides for the use of the salts according to the invention for treatment and/or prophylaxis of disorders, especially the disorders mentioned above.
The present invention further provides for the use of the salts according to the invention for production of a me- dicament for treatment and/or prophylaxis of disorders, especially the disorders ned above.
The present invention further provides the salts according to the invention for use in a method for treatment and/or prophylaxis of heart failure, pulmonary hypertension, c obstructive pulmonary e, , kidney failure, nephropathy, fibrotic disorders of the internal organs and dermatological fibroses.
The present invention further provides medicaments which comprise at least one compound of the ilqion, typically together with one or more inert, ic, phannaceutically suitable excipients, and for the use t ereof for the aforementioned purposes.
[Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp The salts of the invention can act systemically and/or locally. For this purpose, they can be administered in a suitable manner, for e by the oral, parenteral, pulmonal, nasal, sublingual, lingual, buccal, rectal, dermal, transdennal, conjunctiva] or otic route, or as an implant or stent.
The salts of the invention can be administered in administration forms suitable for these administration routes, Suitable administration forms for oral administration are those which work according to the prior art and release the compounds of the invention rapidly and/or in a modified manner and which contain the compounds of the invention in crystalline and/or amorphized and/or dissolved form, for example tablets (uncoated or coated tab- lets, for example with gasnic juice-resistant or ed-dissolution or insoluble coatings which control the re- lease of the compound of the invention), tablets or films/oblates which disintegrate rapidly in the oral cavity, films/lyophilizates, capsules (for example hard or soft gelatin capsules), sugar-coated s, granules, pellets, powders, emulsions, suspensions, aerosols or ons. eral administration can bypass an tion step (eg. intravenously, intraarterially, intracardially, in- naspinally or intralumbally) or include an absorption (eg. tively, intramuscularly, subcutaneously, intra- cutaneously, percutaneously or inn‘aperitoneally). Administration forms suitable for parenteral stration e preparations for injection and infusion in the form of solutions, sions, emulsions, lyophilizates or sterile powders.
For the other administration , suitable examples are inhalation medicaments (including powder inhalers, nebulizers, aerosols), nasal drops, solutions or sprays; tablets for l, sublingual or buccal administration, films/oblates or capsules, suppositories, ear or eye preparations, vaginal capsules, aqueous suspensions ns, shaking es), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g. patches), milk, pastes, foams, dusting powders, implants or stents.
Oral and parenteral administration are preferred, especially oral, intravenous and inhalative administration.
The salts of the ion can be converted to the administration forms mentioned. This can be done in a man- ner known per se, by mixing with inert, nontoxic, pharmaceutically suitable excipients. These excipients in- clude carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (e.g. liquid polyethylene gly- cols), emulsifiers and dispersing or g agents (for example sodium dodecylsulfate, polyoxysorbitan 01eate ), s (for example polyvinylpyrrolidone), tic and natural polymers (for example n), stabi- lizers (eg. antioxidants, for example ascorbic acid), colorants (e.g. inorganic ts, for e iron oxides) and flavor and/or odor correctants.
In general, it has been found to be advantageous in the case of parenteral administration to administer amounts of about 0.00] to 1 mg/kg, preferably about 0.01 to 0.5 mg/kg, of body weight to achieve effective results. In the case of oral administration the dosage is about 0.01 to 100 mg/kg, preferably about 0.01 to 20 mfi and most preferably 0.1 to 10 mg/kg ofbody weight.
The invention furthermore provides a process for preparing the salts according to the invention by dissolving the compound of the formula (I) in the form of the free acid for example in an inert solvent (optionally with addition of a cosolvent) and stirring or shaking with a on of the orming base at a temperature of 10°C to 60°C, preferably at 20°C to 40°C, particularly preferably at 25°C or at room temperature. The resulting crystals of the salts are separated off and the solvent present is removed by drying to constant weight at room temperature or ed temperature.
Suitable inert solvents are lower alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, secbutanol , isobutanol, 1-pentanol, ketones such as acetone, s such as ane, cyclopentane, n-hexane, cyclohexane, or tetrahydrofuran, acetonitrile, toluene, ethyl acetate, 1,4-dioxane or mixtures of the solvents mentioned. Preference is given to acetonitrile, e and isopropanol or mixtures of the solvents mentioned.
Optionally, a cosolvent may be employed. Suitable for this purpose are acetonitrile, acetone, anol, isopropyl acetate, 2-methyltetrafuran, toluene, oxane or else mixtures thereof. Depending on the salt-forming base used, preference is given to toluene, isopropyl acetate or acetonitrile. le salt-forming bases are, in principle, sodium hydroxide, potassium hydroxide, choline bicarbonate, am- monium carbonate, sodium carbonate, ium carbonate, L-lysine, tris(hydroxymethyl)aminomethane, N- methyl-D-glucamine, L-arginine, sodium bicarbonate or potassium bicarbonate. According to the ion, L- lysine, sodium bicarbonate and potassium bicarbonate have been found to be particularly suitable for salt formation.
The preparation processes are generally carried out under heric re. However, it is also possible to operate under elevated or reduced pressure, for example at from 0.5 to 5 bar.
The present invention as claimed herein is described in the following items 1 to 25: 1. A salt of 1-(3-methyloxo-2,3-dihydro-1,3-benzoxazolyl)-2,4-dioxo[(1R)(trifluoromethyl)- 2,3-dihydro-1H-indenyl]-1,2,3,4-tetrahydropyrimidinecarboxylic acid HO O N N H C O 3 N O (I) 17760162_1 (GHMatters) P102736.NZ - 8a - 2. The salt of item 1, which is an amino acid salt or alkali metal salt of 1-(3-methyloxo-2,3-dihydro-1,3- benzoxazolyl)-2,4-dioxo[(1R)(trifluoromethyl)-2,3-dihydro-1H-indenyl]-1,2,3,4- tetrahydropyrimidinecarboxylic acid. 3. The salt of item 1 or 2, which is the lysine salt of 1-(3-methyloxo-2,3-dihydro-1,3-benzoxazolyl)- 2,4-dioxo[(1R)(trifluoromethyl)-2,3-dihydro-1H-indenyl]-1,2,3,4-tetrahydropyrimidine carboxylic acid. 4. The salt of item 1, 2 or 3, which is the L-lysine salt of 1-(3-methyloxo-2,3-dihydro-1,3-benzoxazol yl)-2,4-dioxo[(1R)(trifluoromethyl)-2,3-dihydro-1H-indenyl]-1,2,3,4-tetrahydropyrimidine carboxylic acid. 5. The salt of item 4, characterized in that the X-ray diffractogram of the compound has a peak maximum of the 2 theta angle at 16.9. 6. The salt of item 4 or 5, characterized in that the X-ray diffractogram of the compound has peak maxima of the 2 theta angle at 16.9, 22.3 and 20.0. 7. The salt of item 1 or 2, which is the sodium salt of 1-(3-methyloxo-2,3-dihydro-1,3-benzoxazolyl)- 2,4-dioxo[(1R)(trifluoromethyl)-2,3-dihydro-1H-indenyl]-1,2,3,4-tetrahydropyrimidine carboxylic acid. 8. The salt of item 7, terized in that the X-ray diffractogram of the compound has a peak maximum of the 2 theta angle at 17.6. 9. The salt of item 7 or 8, characterized in that the X-ray diffractogram of the compound has peak maxima of the 2 theta angle at 17.6, 17.9 and 19.1.
. The salt of item 1 or 2, which is the potassium salt of 1-(3-methyloxo-2,3-dihydro-1,3-benzoxazol yl)-2,4-dioxo[(1R)(trifluoromethyl)-2,3-dihydro-1H-indenyl]-1,2,3,4-tetrahydropyrimidine ylic acid. 11. The salt of item 10, characterized in that the X-ray diffractogram of the compound has a peak maximum of the 2 theta angle at 23.7. 12. The salt of item 10 or 11, characterized in that the X-ray diffractogram of the compound has peak maxima of the 2 theta angle at 23.7, 15.3 and 20.5. 13. The salt of any of items 1 to 12 for the treatment of ers. 14. A medicament comprising a salt of any of items 1 to 12 and no r proportions of any other form of the compound of the formula (I). 17760162_1 (GHMatters) P102736.NZ - 8b - . A medicament comprising a compound according to any of items 1 to 12 in more than 90 percent by weight based on the total amount of the compound of the formula (I) present. 16. A process for preparing the compound of any of items 1 to 12, which comprises dissolving the compound of the formula (I) in the form of the free acid. 17. A process of item 16, wherein dissolving the compound of the a (I) in the form of the free acid comprises ng or shaking in an inert solvent with a solution of the salt-forming base at a temperature of 10°C to 60°C. 18. The use of a salt of any of items 1 to 12 in the manufacture of a medicament for the treatment and/or prophylaxis of disorders. 19. The use of item 18, wherein the disorders are cardiovascular, inflammatory, allergic and/or fibrotic disorders.
. The use of item 18 or 19, wherein the medicament comprises a salt of any of items 1 to 12 and no greater proportions of any other form of the nd of the formula (I). 21. The use of item 18 or 19, wherein the medicament comprises a compound ing to any of items 1 to 12 in more than 90 percent by weight based on the total amount of the compound of the a (I) present. 22. The salt of item 1 substantially as herein described with reference to any one of the Examples and/or Figures. 23. The medicament of item 14 or 15 substantially as herein bed with nce to any one of the Examples and/or Figures. 24. The process of item 16 substantially as herein described with reference to any one of the Examples and/or Figures.
. The use of item 18 substantially as herein described with reference to any one of the Examples and/or Figures.
Unless stated otherwise, the percentages in the tests and examples which follow are percentages by weight; parts are parts by weight. Solvent ratios, on ratios and concentration data for the liquid/liquid solutions are based in each case on volume. 17760162_1 (GHMatters) P102736.NZ - 8c - (The next page is page 9.) Experimental part The X-ray diffractograms were recorded at room temperature using an X`Pert PRO (PANalytical) XRD transmission /reflection diffractometer (radiation: , K1, wavelength: 1.5406 Å). There was no sample preparation.
Working examples Preparation of the compound of the formula (I) (free acid) (S)Trifluoromethylindanol 17760162_1 ters) P102736.NZ [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp ation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp Under argon, a solution of 55.7 g (278.3 mmol) of 4-trifluoromethy1indanone, 194 ml (1.391 mol) of tri~ ethylamine and 1.60 g (2.50 mmol) of RuC1(p—cymene)[(S,S)-TsDPEN] (CAS No.: 1921395; TUPAC name: (S,S)-N-(p-toluenesulphonyl)—1,2-diphenylethanediamino(chloro)[1~methyl(propan yl)benzene]ruthenium(ll)) in 258 m1 of dichloromethane was heated to 35°C and, at this temperature, 52.5 ml (1.391 mol) of formic acid were added gradually ion time about 40 min). During the addition, the temper- ature of the reaction mixture increased to 42°C. After the addition was complete, the mixture was stirred at 38°C for a fithher 2 h. All volatile constituents were removed on a rotary evaporator and under HV. Subse- quently, the residue was ved in a little dichloromethane and purified using 1 kg of silica gel t: first 3 liters of cyclohexane/ethyl acetate 5:1, then 6 liters of cyclohcxane/ethyl acetate 1:1). The suitable fractions were concentrated on a rotary evaporator and the product was dried under HV. This gave 51.2 g (90% of theo- ry) of the title compound. 1Irl-NMR (400MHz, DMSO'dG): 6 [ppm]= 1.76 - 1.91 (m, 1H), 2.40 (ddt, 1H), 2.86 (dt, 1H), 3.01 - 3.13 (in, 1H), 5.09 (q, 1H), 5.45 (d, 1H), 7.38 - 7.48 (1n, 1H), 7.55 (d, 1H), 7.62 (d, 1H).
Chiral analytical HPLC (Method 25): R1= 7.49 min; 99 % ee Ethyl _ 1:13-methyl~2—oxo-2,3-dihydr0-l,3-benchxazgl-6;xl_}¢2,4-dioxo—l ,2,3,4—tetrahydrogyg'mjdinej- carboxylate \—-o H3C\ ‘— N N O k E N o/ O H 40.0 g (243.7 mmol) of 6—aminomethyl-l,3-benzoxazol-2(3H)—one were initially charged in 2.5 l of ethanol, and 63.2 g (243.7 mmol) of ethyl 3~ethoxy[(ethoxycarbonyl)carbamoyl]acrylate (for preparation see: Senda, Shigeo; Hirota, Kosaku; Notani, , Chemical & Pharmaceutical Bulletin (1972), 20(7), 1380—8) were add- ed. After a few minutes, a thick suspension formed. This mixture was heated to reflux ature for 1.5 h. Af~ ter cooling slightly (about 60°C), 27.3 g (243.7 mmol) of potassium tert-butoxide were added and the reaction e was stirred further at reflux temperature for 4.5 h. For workup, the reaction suspension was cooled slightly (about 60°C), then stirred into about 10 liters of cold 1N hloric acid. The solid was 11le off with n, washed with water and dried in a vacuum drying cabinet at 70°C overnight. This gave 64.0 g (79% oftheory) of the title compound.
[Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp ation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp LC-MS (Method 1): Rt = 0.59 min; MS (ESIpos): 1n/z = 332 (M+H)+. lH-NMR (400MHz, DMSO~d6): 5 [ppm] = 1.22 (t, 3H), 3.38 (s, 3H), 4.17 (q, 2H), 7.38 (s, 2H), 7.59 (s, 1H), 8.26 (s, IR), 1169 (s, 1H).
Ethyl 1~(3~methy1oxog 3-dih ro-l 3-benzoxazol 1 -2 4-diox0 rifluorometh l -2 3-dih dro_- ll—ljndeni—yl -1 2 3 4-tetrah dro ‘ idine-S-carboxylate (R enantiomer) H3CVO ¢o Method A: Under argon, a on of 200 mg (0.60 mmol) of ethyl ethyloxo-2,3-dihydro-1,3- benzoxazoly1)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-S-carboxylate (see above) and 475 mg (1.81 mmol) of tn'phenylphosphine in THF/DMF 1:1 (7.6 ml) was cooled to -30°C. 238 pl (1.20 mmol) of diisopropyl azodicarboxylate were added se and then a solution of 146 mg (0.69 trunol) of (lS)—4- (trifluoromethyl)indan~l-ol (see above) in about 1 ml of THF was added dropwise. The reaction mixture was warmed to room temperature and stirred at room temperature for 30 min. For workup, the mixture was cooled to 0°C, 5 m1 of 1M hydrochloric acid were added and the mixture was warmed to room temperature and stirred for 30 min. The mixture was then extracted with ethyl acetate. The organic phase was washed twice with 1M hydrochloric acid and once with saturated sodium chloride solution, dried over magnesium sulfate and - trated under reduced pressure. The residue was ted to extractive stirring with ethanol, and the precipitated solid was filtered off with suction and discarded. The filtrate was concentrated, dissolved in a little dichloro~ methane and purified by flash chromatography (dichloromethane/methanol 120:1-) 20:1). This gave 135 mg (43% of theory) of the title compound in about 95% purity.
LC-MS (Method 1): R. = 1.13 min; m/z = 5 I6 (M+H)+. 1H-NMR (400MHz, DMSO-d5): 5 [ppm] = 1.22 (t, 3H), 2.37 — 2.43 (m, 1H), 2.43 ~ 2.48 (m, 1H, partially ob— scured by DMSO ), 3.03 — 3.14 (m, 1H), 3.22 - 3.30 (m, 1H, partially obscured by water signal), 3.38 (s, 3H), 4.18 (q, 2H), 6.34 - 6.56 (m, 1H), 7.32 - 7.43 (m, 3H), 7.45 - 7.50 (in, 1H), 7.53 (d, 1H), 7.55 ~ 7.64 (m, 1H), 8.35 (s, 1H).
In an analogous ment, it was possible to isolate a fraction with 99% purity. For this batch, the specific tical rotation measured was: Specific l rotation: 0. 02° = +132.9°, (chloroform, c = 0.395 g/100 ml).
Method B: Under argon, a solution of 5.0 g (15.1 mmol) of ethyl 1-(3-methyl-2—oxo-2,3-dih)gl,3- benzoxazolyl)—2,4-dioxo-I,2,3,4—tetrahydropyrimidine—S~carboxylate (see above), 6.73 g (25.7 rmnol) of tri- [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp phenylphosphine and 3.66 g (18.1 mmol) of (1S)(trifluoromethyl)indan-l-ol (see above) was initially d in 240 ml of DMF/THF 2:1 (v/v) and cooled to -15°C. 4.76 ml (24.15 mmol) of diisopropyl azodicar- boxylate was slowly added dropwise at such a rate that the temperature of the reaction mixture did not rise above -10°C. At the end of the addition, the mixture was stirred at -10°C for another 1 h, then warmed to room temperature and poured onto 1.3 1 of water. The mixture was extracted twice with 300 ml each time of ethyl ac- etate. The combined organic phases were washed with a ted sodium chloride solution, dried over magne- sium sulfate and freed of the solvent on a rotary evaporator. The residue (18 g) was purified in two chromatog- raphy steps: first using a 200 g silica gel column with dichloromethane/acetone 97.5:2.5 as the mobile phase.
The ing product-containing fractions were concentrated and the residue was applied again to a 200 g silica gel . 2.5 l of exane/ethyl e 1:1 as mobile phase were used to elute fiirther impurities, then the desired product was eluted from the column with dichloromethane/methanol 95:5. This gave 3.40 g (44% of theory) of the title compound in 95% purity (the NMR showed about 5% ethyl acetate). A fimher 920 were obtainable by a new ation of a mixed fraction. Total yield: 4.32 g (56% of theory).
LC-MS (Method 1): R = 1.15 min; m/z = 516 (M+H)*.
'H-NMR (400MHz, CD2C12): 5 [ppm] = 1.31 (t, 3H), 2.37 - 2.49 (m, 1H), 2.59 (dtd, 1H), 3.14 (dt, 1H), 3.40 (s, 3H), 3.42 - 3.53 (m, 1H), 4.29 (q, 2H), 6.54 - 6.68 (m, 1H), 7.06 (d, 1H), 7.17 (d, 1H), 7.22 (s, 1H), 7.26 ~ 7.36 (111,211), 7.49 (d, 1H), 8.28 (s, 1H). 1—|3~Methylogto-2Q-dihydro-1,3—benzoxazolyll-2,4-dioxofl1R)—4-Lt_rifluoromethyll—2,3—dihydro-1H- inden-l ii I- l ,2,3,4-tetrahydropvrimidine-Scaribox‘vliciacid LR enantiomer) 3.40 g (6.60 nnnol) of ethyl 1-(3~methy1oxo-2,3-dihydro-1,3-benzoxazolyl)-2,4-dioxo[(1R) oromethyl)—2,3-dihydro-1H-inden-l-yl]-l,2,3,4-tetrahydropyrimidine-S—carboxylate (see above) were stirred in 44 m1 of glacial acetic acid and 22 ml of concentrated hydrochloric acid at reflux temperature for 1 h.
After cooling slightly (about 60°C), the e was fully concentrated under reduced pressure. 50 m1 of iso~ propanol were added to the amorphous residue and the mixture was heated to reflux for 15 min, in the course of which a solid formed. The suspension was then cooled to 10°C and then the solid was filtered off with suction.
The solid was washed twice with 15 ml each time of isopropanol, filtered off with suction and dried under high vacuum. This gave 2.53 g (79% of theory) of the title compound. a LC-MS (Method 1): R1 = 1.12 min; m/z = 488 (M+H)*.
Chiral analytical HPLC (Method 14): R1: 13.3 min; about 99 % ee ation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp ed set by jennyp IH-NMR (400MHz, CD2C12): 5 [ppm]: 2.40 - 2.52 (m, 1H), 2.59 - 2.72 (in, 11-1), 3.12 — 3.25 (m, 1H), 3.41 (s, 3H), 3.44 — 3.56 (m, 1H), 6.58 - 6.69 (m, 1H), 7.04 - 7.11 (m, 1H), 7.15 - 7.21 (m, 1H), 7.24 (br.s, 18), 7.29 - 7.38 (m, 2H), 7.53 (s, 1H), 8.54 (s, 1H), 12.39 (br. s, 1H).
Specific rotation 0. [>20 = +135.3° (methanol, 0 = 0.43).
In an analogous experiment, the specific rotation of the product was measured in chloroform: a 920 = +159.5° (chloroform, c = 0.395).
An X~ray structure analysis in the complex with e confirmed the R configuration for this enantiomer.
Example 1 Preparation of the L-lfiine salt of 1:13-mefl11112-gx0-2l3fijhydro-l,3—benzoxanxl)-2,4—dioxo—3—l (111)74- 1trifluoromethvl1-2.3-dihytirtz-l H-inden-l-yl|-1.2,3,4-tetrahydropm’midine-S-carboxxlic ac_id About 300 mg of 1-(3-methyloxo-2,3—dihydro-1,3-benzoxazolyl)-2,4-dioxo—3-[(1R)—4-(trifluoromethyl)- 2,3-dihydro-1H-indenyl]-1,2,3,4-tetrahydropy1imidinecarboxylic acid (free acid) were dissolved in 30 m1 of acetonitrile. With pivoting, 30 ml of toluene were added as cosolvent. A solution of 90 mg of ne in 10 m1 of water was then added, and the mixture was stirred at room temperature overnight. The suspension was then filtered and the residue was dried at room temperature and ambient humidity. The residue was examined by X-ray diffractometry and corresporids to the title compound.
Example 2 Emparation of the sodium salt of H3~methyl~2-ox0-2‘3;dihxdro-1,35benzoxazol—6-yl1-2.4-dioxoIf119-3; ttrifluorornethyl)-2,3-dihydro-11:I_;inden:l111;] -teu'ahxdropyrimidme-S-carboxylic acid About 300 mg of l-(3~methyloxo-2,3-dihydro-1,3-benzoxazolyl)-2,4-dioxo[(1R)—4—(trif1uoromethyl)- hydro—1H-inden-l-yI]-1,2,3,4—tetrahydropyrimidine-S-carboxylic acid (free acid) were dissolved in 30 ml of acetonitrile. With pivoting, 30 m1 of isopropyl acetate were added as cosolvent. A solution of 65.2 mg of so dium bicarbonate in 10 ml of water was then added, and the mixture was stirred at room temperature for 60 min. The suspension was then filtered and the residue was dried at room temperature and ambient humidity.
The residue was examined by X-ray diffractometry and corresponds to the title nd.
Example 3 Preparation of the potassium salt of 1- 3-meth Ioxo-2 3-dih dro-l 3-benzoxazolxl[-2.4-dioxol11R1 oromethyl)-2,3-dihydro- lH-inden- 1-v1|~1,2,3.4-tetrahytmmtnidinecarboxylic acid About 300 mg of 1-(3-methyloxo-2,3-dihydro-1,3-benzoxazolyl)-2,4-dioxo[(1R)(tn'fluoromethyl)- hydro-1H-indenyl]-1,2,3,4-tetrahydropyrimidinecarboxylic acid (free acid) were dissolved in 30 ml of acetonitrile. With pivoting, a further 30 ml of acetonitiile were added. A solution of 85.1 mg of p ium bicarbonate in 10 ml of water was then added, and the e was stirred at room temperature for 60 min. The [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp _13_ suspension was then filtered and the residue was dried at room temperature and ambient humidity. The residue was ed by X-ray diffractometry and corresponds to the title compound.
Table 1: X-ray tometry oftheflee acid ofI-(3-methyl0xo—2,3—dihydr0-1,3-benzoxazoIyl)-2,4-dz'oxo- 3-[(1R)(trzflu0romethyD-2,3-dihydro-1H»inden—1—yl]-1,2,3,4-tetrahydropyrimidine—5—carb0xylic acid and its salts Peak maximum [2 theta] Lysine salt Sodium salt Potassium salt [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp [Annotation] jennyp Unmarked set by jennyp [Annotation] jennyp None set by jennyp [Annotation] jennyp MigrationNone set by jennyp ation] jennyp Unmarked set by jennyp Peak maximum {2 theta] Lysine salt Sodium salt Potassium salt 27.] 27.8 28.5 29.0 29.1 .1 .4 Briefdescription ofthefigures Figure 1: X-ray diffractogram of the L-lysine salt of l-(3-methyloxo-2,3-dihydro-l,3-benzoxazolyl)-2,4- dioxo[(1R)—4-(trifluoromethyl)-2,3~dihydro-1H-inden-l-y1]-1,2,3,4-tetrahydropyrimidinecarboxylic acid Figure 2: X-ray diffractogram of the sodium salt of 1-(3-methyloxo-2,3—dihydro—1,3-benzoxazol-6‘yl)-2,4- dioxo[(1 R)(trifluoromethyl)—2,3-dihydro-1H—inden—1-yl]- 1,2,3,4-tetrahydr0pyrimidine—5~carboxylic acid Figure 3: X-ray tog'ram of the potassium salt of 1—(3—methyloxo-2,3-dihydro-l,3-benzoxazolyl)- 2,4~dioxo[(1R)—4-(tn'fluoromethyl)—2,3-dihydro-lH-inden-l-yl]«1,2,3,4-tetrahydropyrimidine-5«carboxylic acid
Claims (22)
1. A salt of 1-(3-methyloxo-2,3-dihydro-1,3-benzoxazolyl)-2,4-dioxo[(1R)(trifluoromethyl)-
2.,3-dihydro-1H-indenyl]-1,2,3,4-tetrahydropyrimidinecarboxylic acid HO O N N H C O 3 N O (I) 5 2. The salt as claimed in claim 1, which is an amino acid salt or alkali metal salt of 1-(3-methyloxo-2,3- dihydro-1,3-benzoxazolyl)-2,4-dioxo[(1R)(trifluoromethyl)-2,3-dihydro-1H-indenyl]- 4-tetrahydropyrimidinecarboxylic acid.
3. The salt as claimed in claim 1 or 2, which is the lysine salt of ethyloxo-2,3-dihydro-1,3- benzoxazolyl)-2,4-dioxo[(1R)(trifluoromethyl)-2,3-dihydro-1H-indenyl]-1,2,3,4- 10 ydropyrimidinecarboxylic acid.
4. The salt as claimed in claim 1, 2 or 3, which is the L-lysine salt of 1-(3-methyloxo-2,3-dihydro-1,3- benzoxazolyl)-2,4-dioxo[(1R)(trifluoromethyl)-2,3-dihydro-1H-indenyl]-1,2,3,4- tetrahydropyrimidinecarboxylic acid.
5. The salt as claimed in claim 4, characterized in that the X-ray diffractogram of the compound has a peak 15 maximum of the 2 theta angle at 16.9.
6. The salt as claimed in claim 4 or 5, characterized in that the X-ray diffractogram of the compound has peak maxima of the 2 theta angle at 16.9, 22.3 and 20.0.
7. The salt as claimed in claim 1 or 2, which is the sodium salt of 1-(3-methyloxo-2,3-dihydro-1,3- benzoxazolyl)-2,4-dioxo[(1R)(trifluoromethyl)-2,3-dihydro-1H-indenyl]-1,2,3,4- 20 tetrahydropyrimidinecarboxylic acid.
8. The salt as claimed in claim 7, characterized in that the X-ray ctogram of the compound has a peak maximum of the 2 theta angle at 17.6.
9. The salt as claimed in claim 7 or 8, characterized in that the X-ray diffractogram of the compound has peak maxima of the 2 theta angle at 17.6, 17.9 and 19.1. 17760162_1 (GHMatters) P102736.NZ
10. The salt as claimed in claim 1 or 2, which is the potassium salt of 1-(3-methyloxo-2,3-dihydro-1,3- benzoxazolyl)-2,4-dioxo[(1R)(trifluoromethyl)-2,3-dihydro-1H-indenyl]-1,2,3,4- tetrahydropyrimidinecarboxylic acid.
11. The salt as claimed in claim 10, characterized in that the X-ray diffractogram of the compound has a 5 peak maximum of the 2 theta angle at 23.7.
12. The salt as claimed in claim 10 or 11, characterized in that the X-ray diffractogram of the compound has peak maxima of the 2 theta angle at 23.7, 15.3 and 20.5.
13. The salt as claimed in any of claims 1 to 12 for the treatment of disorders.
14. A medicament sing a salt as claimed in any of claims 1 to 12 and no greater proportions of any 10 other form of the compound of the formula (I).
15. A medicament sing a compound according to any of Claims 1 to 12 in more than 90 percent by weight based on the total amount of the compound of the formula (I) present.
16. A process for preparing the nd as claimed in any of claims 1 to 12, which ses dissolving the compound of the formula (I) in the form of the free acid. 15
17. A process as claimed in claim 16, wherein dissolving the compound of the formula (I) in the form of the free acid comprises ng or shaking in an inert solvent with a solution of the salt-forming base at a temperature of 10°C to 60°C.
18. The use of a salt as claimed in any of claims 1 to 12 in the manufacture of a medicament for the treatment and/or prophylaxis of disorders. 20
19. The use as claimed in claim 18, wherein the disorders are cardiovascular, inflammatory, allergic and/or fibrotic disorders.
20. The use as claimed in claim 18 or 19, wherein the medicament comprises a salt as claimed in any of claims 1 to 12 and no greater proportions of any other form of the compound of the a (I).
21. The use as claimed in claim 18 or 19, n the medicament comprises a compound according to any 25 of Claims 1 to 12 in more than 90 percent by weight based on the total amount of the compound of the formula (I) present.
22. The salt as claimed in claim 1 substantially as herein described with reference to any one of the es and/or
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13192177 | 2013-11-08 | ||
| EP13192177.7 | 2013-11-08 | ||
| PCT/EP2014/073801 WO2015067652A1 (en) | 2013-11-08 | 2014-11-05 | Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ719532A NZ719532A (en) | 2021-06-25 |
| NZ719532B2 true NZ719532B2 (en) | 2021-09-28 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI304062B (en) | N-(pyridin-2-yl)-sulfonamide derivatives | |
| US10300062B2 (en) | Bicyclically substituted uracils and the use thereof | |
| JP7368419B2 (en) | Aldose reductase inhibitors and their use | |
| WO2018196805A1 (en) | Polymorph of compound, preparation method therefor and use thereof | |
| US9695131B2 (en) | Substituted uracils as chymase inhibitors | |
| US9926305B2 (en) | Salts | |
| JP2003514821A (en) | Imidazole compounds used as phosphodiesterase VII inhibitors | |
| JP2003522772A (en) | Benzothiazoles as TNF and PDE-IV inhibitors | |
| JP2021515015A (en) | Crystalline morphology of SGC stimulators | |
| WO2015150364A1 (en) | Substituted benzotriazinone butane acids and use thereof | |
| EP3126339A1 (en) | 2,5-disubstituted cyclopentane carboxylic acids and use thereof | |
| NZ719532B2 (en) | Salts of 1-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1r)- 4-(trifluormethyl)-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid | |
| US20240317764A1 (en) | Salts and solid forms of a compound having apj receptor activity | |
| KR20030065564A (en) | Benzoylpyridazines | |
| JP3265134B2 (en) | Nitrogen-containing bicyclic heterocyclic derivative and pharmaceutical preparation containing the same | |
| HK1222171B (en) | Salts of compounds | |
| JP2897310B2 (en) | Quinazoline derivatives and their salts | |
| TW200303744A (en) | Water soluble phenylglycine derivatives | |
| HK1223925B (en) | Aldose reductase inhibitors and uses thereof | |
| TW200403063A (en) | Novel compounds |